Esra Eraslan Aydemir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Esra Eraslan Aydemir has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Murat Faik Erdoğan
Department of Endocrinology and Metabolism, Ankara University Medical Faculty, Ankara, Türkiye
2 shared publications - Mustafa Sahin
Department of Endocrinology and Metabolism, Faculty of Medicine, Ankara University, Ankara, Türkiye
2 shared publications - Rıfat Emral
Ankara University
2 shared publications - Özgür Demir
Department of Endocrinology and Metabolism, Ankara University School of Medicine, Ankara, Türkiye
2 shared publications Asena Gökçay Canpolat
Department of Internal Medicine, Division of Endocrinology, Ankara University Faculty of Medicine, Ankara, Türkiye
1 shared publication- Asena Gökçay Canpolat
Department of Endocrinology and Metabolism, Ankara University School of Medicine, Ankara, Turkey
1 shared publication
Latest Publications
- Open Access
- 1 June 2026
- Published by AVES YAYINCILIK A.Ş. in Endocrinology Research and Practice
- Vol. 30 (3)
Fifty Years of Misdiagnosis: Two Sisters with X-Linked Hypophosphatemia Misdiagnosed as Achondroplasia
X-linked hypophosphatemia (XLH) is the most common inherited form of hypophosphatemic rickets, caused by inactivating mutations in the phosphate-regulating endopeptidase homolog, X-linked (PHEX) gene. Despite its distinct clinical and biochemical features, XLH can be misdiagnosed as achondroplasia because of overlapping skeletal manifestations. Two sisters, aged 53 and 60 years, who were misdiagnosed with achondroplasia for more than 5 decades were later diagnosed with XLH. Both patients presented with diffuse bone pain, severe skeletal deformities, including coxa vara with shepherd’s crook deformity and femoral bowing and a history of spontaneous dental abscesses. Laboratory testing revealed hypophosphatemia with normocalcemia. Family history showed an X-linked dominant inheritance pattern, with an affected father, all 4 sisters affected, and 3 unaffected brothers—inconsistent with achondroplasia. Whole-exome sequencing identified a novel heterozygous PHEX variant, c.207_212del (p.K69_V70del), classified as a variant of uncertain significance (VUS) per American College of Medical Genetics (ACMG) guidelines. Notably, the first patient had undergone parathyroidectomy 24 years earlier, likely reflecting tertiary hyperparathyroidism as a long-term complication of undiagnosed XLH. This report highlights that careful evaluation of family history, combined with simple biochemical tests, can prevent decades of misdiagnosis and its associated morbidity. Cite this article as: Aydemir EE, Ertürk Ş., Leblebici CB, Karabulut HG, Demir. Fifty years of misdiagnosis: two sisters with X-linked hypophosphatemia misdiagnosed as achondroplasia. Endocrinol Res Pract. 2026;30(3):213-216.
- 1 June 2026
- Published by AVES YAYINCILIK A.Ş. in Endocrinology Research and Practice
- Vol. 30 (3)
Open AccessFifty Years of Misdiagnosis: Two Sisters with X-Linked Hypophosphatemia Misdiagnosed as Achondroplasia
X-linked hypophosphatemia (XLH) is the most common inherited form of hypophosphatemic rickets, caused by inactivating mutations in the phosphate-regulating endopeptidase homolog, X-linked (PHEX) gene. Despite its distinct clinical and biochemical features, XLH can be misdiagnosed as achondroplasia because of overlapping skeletal manifestations. Two sisters, aged 53 and 60 years, who were misdiagnosed with achondroplasia for more than 5 decades were later diagnosed with XLH. Both patients presented with diffuse bone pain, severe skeletal deformities, including coxa vara with shepherd’s crook deformity and femoral bowing and a history of spontaneous dental abscesses. Laboratory testing revealed hypophosphatemia with normocalcemia. Family history showed an X-linked dominant inheritance pattern, with an affected father, all 4 sisters affected, and 3 unaffected brothers—inconsistent with achondroplasia. Whole-exome sequencing identified a novel heterozygous PHEX variant, c.207_212del (p.K69_V70del), classified as a variant of uncertain significance (VUS) per American College of Medical Genetics (ACMG) guidelines. Notably, the first patient had undergone parathyroidectomy 24 years earlier, likely reflecting tertiary hyperparathyroidism as a long-term complication of undiagnosed XLH. This report highlights that careful evaluation of family history, combined with simple biochemical tests, can prevent decades of misdiagnosis and its associated morbidity. Cite this article as: Aydemir EE, Ertürk Ş., Leblebici CB, Karabulut HG, Demir. Fifty years of misdiagnosis: two sisters with X-linked hypophosphatemia misdiagnosed as achondroplasia. Endocrinol Res Pract. 2026;30(3):213-216.
- Open Access
- 18 May 2026
- Published by Springer Nature in Pituitary
- Vol. 29 (3) , 88
Hormonal staining patterns and clinical outcomes in acromegaly: a 15-year single-center study
Purpose: Acromegaly is most commonly caused by pituitary somatotroph adenomas, a substantial proportion of which exhibit prolactin (PRL) expression on immunohistochemistry. However, the clinical relevance and prognostic implications of this pathological phenotype remain controversial. We aimed to compare pathological features and treatment outcomes of growth hormone/prolactin (GH/PRL)–positive adenomas with GH-only adenomas. Methods: We retrospectively analyzed 90 patients with acromegaly who underwent transsphenoidal surgery between 2010 and 2025. Adenomas were classified according to immunohistochemical staining as GH-only, GH/PRL, or other subtypes. Clinical, biochemical, radiological, and treatment outcomes were compared across groups. Results: Of 90 adenomas, 47 (52.2%) were GH-only, 39 (43.3%) GH/PRL, and 4 (4.4%) other PIT-1 lineage adenomas. Postoperative remission was achieved in 32 patients (35.6%), with no significant difference between GH-only and GH/PRL adenomas. In multivariable analysis, optic chiasm compression was independently associated with lower odds of remission (OR 0.212, 95% CI 0.049–0.910; p = 0.037). Among 45 patients receiving SSA therapy, 25 (55.6%) achieved biochemical response. Perinuclear CK8/18 staining (OR 4.839, 95% CI 1.198–19.540; p = 0.027) and T2-weighted MRI hypointensity (OR 5.464, 95% CI 1.284–23.250; p = 0.022) were independently associated with SSA response. Although Ki-67 was higher in GH/PRL adenomas, it was not associated with treatment outcomes. Conclusion: Despite higher proliferative activity, GH/PRL adenomas did not demonstrate inferior surgical or medical outcomes compared with GH-only adenomas. Prognosis appears to be driven primarily by anatomical features and cytokeratin patterns, supporting individualized treatment strategies.
- 18 May 2026
- Published by Springer Nature in Pituitary
- Vol. 29 (3) , 88
Open AccessHormonal staining patterns and clinical outcomes in acromegaly: a 15-year single-center study
Purpose: Acromegaly is most commonly caused by pituitary somatotroph adenomas, a substantial proportion of which exhibit prolactin (PRL) expression on immunohistochemistry. However, the clinical relevance and prognostic implications of this pathological phenotype remain controversial. We aimed to compare pathological features and treatment outcomes of growth hormone/prolactin (GH/PRL)–positive adenomas with GH-only adenomas. Methods: We retrospectively analyzed 90 patients with acromegaly who underwent transsphenoidal surgery between 2010 and 2025. Adenomas were classified according to immunohistochemical staining as GH-only, GH/PRL, or other subtypes. Clinical, biochemical, radiological, and treatment outcomes were compared across groups. Results: Of 90 adenomas, 47 (52.2%) were GH-only, 39 (43.3%) GH/PRL, and 4 (4.4%) other PIT-1 lineage adenomas. Postoperative remission was achieved in 32 patients (35.6%), with no significant difference between GH-only and GH/PRL adenomas. In multivariable analysis, optic chiasm compression was independently associated with lower odds of remission (OR 0.212, 95% CI 0.049–0.910; p = 0.037). Among 45 patients receiving SSA therapy, 25 (55.6%) achieved biochemical response. Perinuclear CK8/18 staining (OR 4.839, 95% CI 1.198–19.540; p = 0.027) and T2-weighted MRI hypointensity (OR 5.464, 95% CI 1.284–23.250; p = 0.022) were independently associated with SSA response. Although Ki-67 was higher in GH/PRL adenomas, it was not associated with treatment outcomes. Conclusion: Despite higher proliferative activity, GH/PRL adenomas did not demonstrate inferior surgical or medical outcomes compared with GH-only adenomas. Prognosis appears to be driven primarily by anatomical features and cytokeratin patterns, supporting individualized treatment strategies.
- Open Access
- 30 April 2026
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 43 (5) , 230-237
Anti-Thyroglobulin Antibodies as a Surrogate Tumor Marker for the Follow-Up of the Differentiated Thyroid Carcinoma: Clinical Implications and Pitfalls
Antithyroglobulin antibodies (TgAb) are present in 10-25% of patients with differentiated thyroid cancer (DTC) and significantly affect the reliability of serum thyroglobulin (Tg) measurements during follow-up. Beyond causing assay interference, TgAb have emerged as independent surrogate tumor markers with prognostic implications. This review summarizes the current evidence on antithyroglobulin antibody biology, measurement methodologies, interference dynamics, and clinical utility as surrogate tumor markers in DTC surveillance. A narrative synthesis of the relevant English-language literature was performed, focusing on key clinical studies and recent guidelines. TgAb can lead to the underestimation of Tg levels in immunometric assays, potentially masking residual disease. Trend monitoring, rather than absolute antithyroglobulin antibody values, provides superior prognostic information; declining trends indicate favorable outcomes, whereas rising trends are associated with disease persistence or recurrence. De novo antithyroglobulin antibody positivity does not appear to serve as an early biomarker of recurrence. In antithyroglobulin antibody-positive patients, imaging-based surveillance, particularly neck ultrasonography, remains the cornerstone of follow-up. In conclusion, TgAb act as both interferents and surrogate tumor markers in DTC surveillance, and the integrated use of antithyroglobulin antibody trends and imaging is necessary for the optimal management of antithyroglobulin antibody-positive patients.
- 30 April 2026
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 43 (5) , 230-237
Open AccessAnti-Thyroglobulin Antibodies as a Surrogate Tumor Marker for the Follow-Up of the Differentiated Thyroid Carcinoma: Clinical Implications and Pitfalls
Antithyroglobulin antibodies (TgAb) are present in 10-25% of patients with differentiated thyroid cancer (DTC) and significantly affect the reliability of serum thyroglobulin (Tg) measurements during follow-up. Beyond causing assay interference, TgAb have emerged as independent surrogate tumor markers with prognostic implications. This review summarizes the current evidence on antithyroglobulin antibody biology, measurement methodologies, interference dynamics, and clinical utility as surrogate tumor markers in DTC surveillance. A narrative synthesis of the relevant English-language literature was performed, focusing on key clinical studies and recent guidelines. TgAb can lead to the underestimation of Tg levels in immunometric assays, potentially masking residual disease. Trend monitoring, rather than absolute antithyroglobulin antibody values, provides superior prognostic information; declining trends indicate favorable outcomes, whereas rising trends are associated with disease persistence or recurrence. De novo antithyroglobulin antibody positivity does not appear to serve as an early biomarker of recurrence. In antithyroglobulin antibody-positive patients, imaging-based surveillance, particularly neck ultrasonography, remains the cornerstone of follow-up. In conclusion, TgAb act as both interferents and surrogate tumor markers in DTC surveillance, and the integrated use of antithyroglobulin antibody trends and imaging is necessary for the optimal management of antithyroglobulin antibody-positive patients.
- 31 December 2025
- Published by Ankara University in Ankara Üniversitesi Tıp Fakültesi Mecmuası
- Vol. 78 (4) , 295-306
Diagnosis and Treatment of Primary, Secondary, and Functional Male Hypogonadism: A Narrative Review
Male hypogonadism refers to a condition characterized by reduced testosterone production or impaired sperm production. Traditionally, it was classified into two categories: congenital and acquired hypogonadism. However, with the emergence of the concept of functional hypogonadism, which develops as a result of chronic diseases, medications, or aging, male hypogonadism is now considered under three subtypes. The clinical manifestations and treatment strategies vary depending on the underlying cause of hypogonadism. Additionally, the desire for fertility significantly influences the treatment protocol. This systematic review examines the diagnostic and therapeutic approaches to primary, secondary, and functional male hypogonadism.
- 31 December 2025
- Published by Ankara University in Ankara Üniversitesi Tıp Fakültesi Mecmuası
- Vol. 78 (4) , 295-306
Diagnosis and Treatment of Primary, Secondary, and Functional Male Hypogonadism: A Narrative Review
Male hypogonadism refers to a condition characterized by reduced testosterone production or impaired sperm production. Traditionally, it was classified into two categories: congenital and acquired hypogonadism. However, with the emergence of the concept of functional hypogonadism, which develops as a result of chronic diseases, medications, or aging, male hypogonadism is now considered under three subtypes. The clinical manifestations and treatment strategies vary depending on the underlying cause of hypogonadism. Additionally, the desire for fertility significantly influences the treatment protocol. This systematic review examines the diagnostic and therapeutic approaches to primary, secondary, and functional male hypogonadism.
- Open Access
- 17 December 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (7) , 1620-1624
Effects of endocrine disruptors on thyroid hormone synthesis and function and consequences of fetal exposure
Fetal development relies on intricate maternal-fetal-placental interactions, with thyroid hormones playing a critical role in growth and neurogenesis. Exposure to endocrine-disrupting chemicals (EDCs) during pregnancy has emerged as a significant risk factor for thyroid dysfunction and its associated developmental and cognitive disorders. EDCs, including bisphenol A (BPA), polychlorinated biphenyls (PCBs), polybrominated diphenyl ethers (PBDEs), perfluorinated compounds (PFAS), pesticides, and heavy metals, disrupt thyroid hormone synthesis, secretion, and metabolism. Mechanisms include binding to thyroid hormone receptors, impairing the hypothalamic-pituitary-thyroid axis, and altering thyroid peroxidase activity. BPA exposure, for instance, reduces free and total T4 levels and interferes with deiodinase activity. Similarly, PCBs and PBDEs are associated with lower thyroxine levels and long-term behavioral issues in offspring. Pesticides and heavy metals exacerbate thyroid dysfunction by affecting hormone synthesis and receptor interactions. Genetic predisposition, iodine deficiency, and autoimmune conditions further increase susceptibility to EDC-related thyroid diseases. Given the vulnerability of the early pregnancy period and the prevalence of EDCs in the environment, reducing exposure and implementing regulatory measures are essential to mitigate adverse effects on maternal and fetal thyroid health. Future research should prioritize the mechanisms of EDC-induced thyroid dysfunction and potential interventions to protect at-risk populations.
- 17 December 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (7) , 1620-1624
Open AccessEffects of endocrine disruptors on thyroid hormone synthesis and function and consequences of fetal exposure
Fetal development relies on intricate maternal-fetal-placental interactions, with thyroid hormones playing a critical role in growth and neurogenesis. Exposure to endocrine-disrupting chemicals (EDCs) during pregnancy has emerged as a significant risk factor for thyroid dysfunction and its associated developmental and cognitive disorders. EDCs, including bisphenol A (BPA), polychlorinated biphenyls (PCBs), polybrominated diphenyl ethers (PBDEs), perfluorinated compounds (PFAS), pesticides, and heavy metals, disrupt thyroid hormone synthesis, secretion, and metabolism. Mechanisms include binding to thyroid hormone receptors, impairing the hypothalamic-pituitary-thyroid axis, and altering thyroid peroxidase activity. BPA exposure, for instance, reduces free and total T4 levels and interferes with deiodinase activity. Similarly, PCBs and PBDEs are associated with lower thyroxine levels and long-term behavioral issues in offspring. Pesticides and heavy metals exacerbate thyroid dysfunction by affecting hormone synthesis and receptor interactions. Genetic predisposition, iodine deficiency, and autoimmune conditions further increase susceptibility to EDC-related thyroid diseases. Given the vulnerability of the early pregnancy period and the prevalence of EDCs in the environment, reducing exposure and implementing regulatory measures are essential to mitigate adverse effects on maternal and fetal thyroid health. Future research should prioritize the mechanisms of EDC-induced thyroid dysfunction and potential interventions to protect at-risk populations.
- 9 October 2025
- Published by Elsevier in Neurophysiologie Clinique
- Vol. 55 (6) , 103114
Comparison of sural and distal sural nerve responses: Diagnostic role of the amplitude ratio in diabetic polyneuropathy
- 9 October 2025
- Published by Elsevier in Neurophysiologie Clinique
- Vol. 55 (6) , 103114
Comparison of sural and distal sural nerve responses: Diagnostic role of the amplitude ratio in diabetic polyneuropathy